Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zephyrus II: Pamrevlumab in Idiopathic Pulmonary Fibrosis
2020-000697-22Phase 3Terminated
- Sponsor
- FibroGen
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Pamrevlumab 30 mg/kg IV with Placebo IV (2 arms). Primary endpoint: Proportion of subjects with disease progression. Started Mar 2020; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2020-000697-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000697-22.